ChiCTR-OCH-12002406已完成Unknown
Risk-stratification Treatment Directed by Minimal Residual Disease in Acute Myeloid Leukemia with t(8;21) in First Complete Remission
no0 个研究点目标入组 110 人开始时间: 2005年6月1日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 110
- 主要终点
- relapse
研究概览
简要总结
To improve outcome in patients with t(8;21) acute myeloid leukemia(AML) in first complete remission (CR) by applying risk-directed therapy that was based on measurements of minimal residual disease (MRD) by quantitative PCR during treatment.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 14 至 60（—）
- 性别
- All
入选标准
- •(1) newly diagnosed AML patients with a positive t(8;21) cytogenetic result or RUX1/RUX1T1 transcripts;
- •(2) between 14 and 60-years-old;
- •(3) in first complete remission (CR1);
- •(4) no contraindications to consolidation chemotherapy or HSCT.
排除标准
- •(1) relapsed AML patients with a positive t(8;21) cytogenetic result or RUX1/RUX1T1 transcripts;
- •(2) less than 14 or more than 60-years-old;
- •(3) in first complete remission (CR1);
- •(4) no contraindications to consolidation chemotherapy or HSCT.
研究组 & 干预措施
1
risk-directed treatment
结局指标
主要结局
relapse
DFS
次要结局
未报告次要终点
研究者
相似试验
Unknown
不适用
基于急性髓系白血病 MRD 调整治疗方案的临床观察ChiCTR2000033235国家自然科学基金青年项目（基金号 81800137）100
招募中
1 期
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)Acute Myeloid LeukemiaNCT07306832AbbVie18
尚未招募
1 期
Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT07432100Mingfeng Zhao20
招募中
2 期
AML-NET : Acute Myeloid Leukemia treated with with NETrin Abs in combination with [AZACITIDINE + VENETOCLAX]2023-503408-10-00Centre Leon Berard, Centre Leon Berard35
招募中
不适用
Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic LeukemiaLeukemiaNCT07258043Hospital General de Mexico45